Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 127

Results For "RI"

10192 News Found

Briefs: Fermenta Biotech and Family Care Hospitals
News | September 20, 2024

Briefs: Fermenta Biotech and Family Care Hospitals

Fermenta Biotech’s API manufacturing facility receives EU GMP compliance certificate


Briefs: Dr. Reddy's Laboratories and Torrent Pharmaceuticals
Drug Approval | September 20, 2024

Briefs: Dr. Reddy's Laboratories and Torrent Pharmaceuticals

USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation


Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO
People | September 20, 2024

Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO

She brings an overall Techno Commercial experience of 22+ Years in various Organizations


Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL
News | September 20, 2024

Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL

Stable profits, low leverage to keep credit profiles comfortable


Dr. Girish Budhrani recognised with ACOIN Gujarat Chapter Oration
People | September 20, 2024

Dr. Girish Budhrani recognised with ACOIN Gujarat Chapter Oration

ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology


Brinton Pharmaceuticals launches UV DOUX lip lightening balm in India
News | September 18, 2024

Brinton Pharmaceuticals launches UV DOUX lip lightening balm in India

Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day


Briefs: Eugia Steriles and Shelter Pharma
Drug Approval | September 18, 2024

Briefs: Eugia Steriles and Shelter Pharma

Eugia Steriles receives EIR from USFDA for new injectable facility


FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer immunotherapy
Drug Approval | September 16, 2024

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer immunotherapy

Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous


Strides receives USFDA approval for Fluoxetine Tabs 60 mg
Drug Approval | September 16, 2024

Strides receives USFDA approval for Fluoxetine Tabs 60 mg

Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules


Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC
Clinical Trials | September 16, 2024

Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC

KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival